Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,189
datasets available to search
ShareScore release 0.9.0
Dataset results
2,189 results for “AML”
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT05183035. IPD Sharing: NO. Countries: 20. Publications: 1.
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
ClinicalTrials.gov study NCT00780598. IPD Sharing: Not stated. Countries: 3. Publications: 3.
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
ClinicalTrials.gov study NCT05641259. IPD Sharing: NO. Countries: 1. Publications: 3.
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)
ClinicalTrials.gov study NCT04547062. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening
ClinicalTrials.gov study NCT04267081. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
ClinicalTrials.gov study NCT04857645. IPD Sharing: NO. Countries: 1. Publications: 1.
2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML
ClinicalTrials.gov study NCT04953780. IPD Sharing: NO. Countries: 1. Publications: 31.
Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.
ClinicalTrials.gov study NCT06946602. IPD Sharing: NO. Countries: 1. Publications: 4.
Maintenance Venetoclax in AML Fit Patients
ClinicalTrials.gov study NCT07244367. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study
ClinicalTrials.gov study NCT00715637. IPD Sharing: Not stated. Countries: 23. Publications: 2.
Selecting a Favorable KIR Donor in Unrelated HCT for AML
ClinicalTrials.gov study NCT01288222. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
ClinicalTrials.gov study NCT01613976. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer
ClinicalTrials.gov study NCT03360006. IPD Sharing: NO. Countries: 1. Publications: 2.
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
ClinicalTrials.gov study NCT01515527. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
ClinicalTrials.gov study NCT01578954. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years
ClinicalTrials.gov study NCT01193400. IPD Sharing: Not stated. Countries: 1. Publications: 1.
G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
ClinicalTrials.gov study NCT02744742. IPD Sharing: YES. Countries: 1. Publications: 1.
Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
ClinicalTrials.gov study NCT00363974. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
ClinicalTrials.gov study NCT00689000. IPD Sharing: Not stated. Countries: 1. Publications: 1.
IL-6: A Marker for AML Chemo Sensitivity
ClinicalTrials.gov study NCT06486350. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.